search
Back to results

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Primary Purpose

Hypertriglyceridemia

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
evinacumab
Placebo
Sponsored by
Regeneron Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertriglyceridemia focused on measuring Severe Hypertriglyceridemia (HTG), Recurrent Acute Pancreatitis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  1. Adults without FCS due to LPL loss of function mutations
  2. Documented history of 1 HTG-associated AP episode within 24 months of screening
  3. Fasting serum TG value >880 mg/dL (10 mmol/L) or >500 mg/dL (5.6mmol/L) determined during the screening period as described in the protocol
  4. Stable dose of lipid-lowering therapy (≥8 weeks) and willingness to maintain a stable regimen throughout the study
  5. Body mass index ≥18.0 and ≤45.0 kg/m2
  6. Compliance with a stable diet and exercise regimen at screening and willingness to continue the diet through the end of the study

Key Exclusion Criteria:

  1. Hospitalization for AP within 4 weeks of screening
  2. Known genetic FCS defined as homozygous or compound heterozygous LoF mutations in LPL as defined in the protocol
  3. Symptomatic gallstone disease within 6 months prior to screening as defined in the protocol
  4. Use of any medication or nutraceutical known to alter serum lipids which has not been part of a stable therapeutic regimen for at least 8 weeks, and there are no plans to change the regimen during the study
  5. Presence of any clinically significant, uncontrolled endocrine disease known to influence serum lipids as defined in the protocol
  6. Has received a COVID-19 vaccination within 1-week of planned start medication or for which the planned COVID-19 vaccination would not be completed 1-week prior to start of the study

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Sites / Locations

  • Radin Cardivascular Medical Group, Inc
  • Yale Cancer Center - Yale University
  • Excel Medical Clinical Trials, LLC
  • Harmony Medical Research Institute, Inc.
  • Northeast Georgia Medical Center
  • NorthShore Medical Group
  • Advocate Medical Group Midwest Heart Specialists
  • Methodist Medical Center of Illiniois - UnityPoint Clinic
  • Quincy Medical Group
  • St. Vincent Medical Group, Inc.
  • University of Kansas Medical Center
  • Johns Hopkins University School of Medicine
  • Minneapolis Heart Institute
  • University of Minnesota
  • Saint Louis University
  • Washington University School of Medicine
  • Northwell Health
  • NYU Langone Hospital - Long Island
  • Weill Cornell Medical College
  • Mt Sinai - Ichan Medical Institute
  • Wake Forest University Health Sciences
  • University of Cincinnati Hospital
  • Penn Medicine: University of Pennsylvania Health System
  • University Of Pittsburgh
  • Medical University of South Carolina
  • University Diabetes & Endocrine Consultants
  • Methodist Dallas Medical Center
  • Sante Clinical Research
  • University of Washington
  • MultiCare Institute for Research
  • West Virginia University Heart & Vascular Institute
  • Wisconsin Center for Advanced Research - a division of GI Associates, LLC
  • Robarts Research Institute
  • Centre Etudes Cliniques Ecogene-21
  • Clinique des maladies lipidiques de Quebec
  • University Hospital Carl Gustav Carus
  • University Hospital of Leipzig
  • Amsterdam University Medical Center (Amsterdam UMC), Academic Medical Center (AMC)
  • Ziekenhuis Rijnstate

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

evinacumab

Placebo

Arm Description

Randomized 1:1

Randomized 1:1

Outcomes

Primary Outcome Measures

Proportion of patients with at least 1 positively adjudicated acute pancreatitis (AP) episode

Secondary Outcome Measures

Percent change in ApoC3
Percent change in fasting triglycerides (TGs)
Percent change in total cholesterol (TC)
Percent change in non-high-density lipoprotein cholesterol (non-HDL-C)
Percent change in ApoB48
Percent change in ApoB100 levels
Percent change in nuclear magnetic resonance (NMR)-determined particle size and number
Number of independently adjudicated episodes of AP per patient

Full Information

First Posted
April 26, 2021
Last Updated
March 20, 2023
Sponsor
Regeneron Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT04863014
Brief Title
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
Official Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Terminated
Why Stopped
Sponsor Decision
Study Start Date
July 12, 2021 (Actual)
Primary Completion Date
February 15, 2023 (Actual)
Study Completion Date
February 15, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Regeneron Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of the study is to determine the proportion of patients with elevated triglycerides (TG), without familial chylomicronemia syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL), and a history of hypertriglyceridemia (HTG)-associated acute pancreatitis (AP) who experience a recurrent episode of AP after treatment with evinacumab versus placebo. The secondary objectives of the study are: To determine the change in the standard lipid profile after therapy with evinacumab versus placebo To determine the changes in specialty lipoprotein parameters (ApoC3, ApoB48, ApoB100, and nuclear magnetic resonance [NMR] lipid profile) after therapy with evinacumab versus placebo To measure the number of AP episodes per patient To assess the safety and tolerability of evinacumab To assess the potential immunogenicity of evinacumab To assess the concentrations of total evinacumab and total angiopoietin-like 3 (ANGPTL3)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertriglyceridemia
Keywords
Severe Hypertriglyceridemia (HTG), Recurrent Acute Pancreatitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
evinacumab
Arm Type
Experimental
Arm Description
Randomized 1:1
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Randomized 1:1
Intervention Type
Drug
Intervention Name(s)
evinacumab
Other Intervention Name(s)
REGN1500, Evkeeza™
Intervention Description
Intravenous infusion every 4 weeks (Q4W)
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Intravenous infusion Q4W
Primary Outcome Measure Information:
Title
Proportion of patients with at least 1 positively adjudicated acute pancreatitis (AP) episode
Time Frame
Up to 52 weeks
Secondary Outcome Measure Information:
Title
Percent change in ApoC3
Time Frame
Baseline to week 52
Title
Percent change in fasting triglycerides (TGs)
Time Frame
Baseline to week 52
Title
Percent change in total cholesterol (TC)
Time Frame
Baseline to week 52
Title
Percent change in non-high-density lipoprotein cholesterol (non-HDL-C)
Time Frame
Baseline to week 52
Title
Percent change in ApoB48
Time Frame
Baseline to week 52
Title
Percent change in ApoB100 levels
Time Frame
Baseline to week 52
Title
Percent change in nuclear magnetic resonance (NMR)-determined particle size and number
Time Frame
Baseline to week 52
Title
Number of independently adjudicated episodes of AP per patient
Time Frame
Up to 52 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Adults without FCS due to LPL loss of function mutations Documented history of 1 HTG-associated AP episode within 24 months of screening Fasting serum TG value >880 mg/dL (10 mmol/L) or >500 mg/dL (5.6mmol/L) determined during the screening period as described in the protocol Stable dose of lipid-lowering therapy (≥8 weeks) and willingness to maintain a stable regimen throughout the study Body mass index ≥18.0 and ≤45.0 kg/m2 Compliance with a stable diet and exercise regimen at screening and willingness to continue the diet through the end of the study Key Exclusion Criteria: Hospitalization for AP within 4 weeks of screening Known genetic FCS defined as homozygous or compound heterozygous LoF mutations in LPL as defined in the protocol Symptomatic gallstone disease within 6 months prior to screening as defined in the protocol Use of any medication or nutraceutical known to alter serum lipids which has not been part of a stable therapeutic regimen for at least 8 weeks, and there are no plans to change the regimen during the study Presence of any clinically significant, uncontrolled endocrine disease known to influence serum lipids as defined in the protocol Has received a COVID-19 vaccination within 1-week of planned start medication or for which the planned COVID-19 vaccination would not be completed 1-week prior to start of the study Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trial Management
Organizational Affiliation
Regeneron Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Radin Cardivascular Medical Group, Inc
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Facility Name
Yale Cancer Center - Yale University
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Facility Name
Excel Medical Clinical Trials, LLC
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33434
Country
United States
Facility Name
Harmony Medical Research Institute, Inc.
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33015
Country
United States
Facility Name
Northeast Georgia Medical Center
City
Gainesville
State/Province
Georgia
ZIP/Postal Code
30501
Country
United States
Facility Name
NorthShore Medical Group
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Facility Name
Advocate Medical Group Midwest Heart Specialists
City
Park Ridge
State/Province
Illinois
ZIP/Postal Code
60068
Country
United States
Facility Name
Methodist Medical Center of Illiniois - UnityPoint Clinic
City
Peoria
State/Province
Illinois
ZIP/Postal Code
61636
Country
United States
Facility Name
Quincy Medical Group
City
Quincy
State/Province
Illinois
ZIP/Postal Code
62301
Country
United States
Facility Name
St. Vincent Medical Group, Inc.
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46290
Country
United States
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Johns Hopkins University School of Medicine
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Facility Name
Minneapolis Heart Institute
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55407
Country
United States
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55422
Country
United States
Facility Name
Saint Louis University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Northwell Health
City
Manhasset
State/Province
New York
ZIP/Postal Code
11030
Country
United States
Facility Name
NYU Langone Hospital - Long Island
City
Mineola
State/Province
New York
ZIP/Postal Code
11501
Country
United States
Facility Name
Weill Cornell Medical College
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Mt Sinai - Ichan Medical Institute
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Wake Forest University Health Sciences
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
University of Cincinnati Hospital
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Facility Name
Penn Medicine: University of Pennsylvania Health System
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University Of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
University Diabetes & Endocrine Consultants
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37411
Country
United States
Facility Name
Methodist Dallas Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75208
Country
United States
Facility Name
Sante Clinical Research
City
Kerrville
State/Province
Texas
ZIP/Postal Code
78028
Country
United States
Facility Name
University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Facility Name
MultiCare Institute for Research
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Facility Name
West Virginia University Heart & Vascular Institute
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Facility Name
Wisconsin Center for Advanced Research - a division of GI Associates, LLC
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Facility Name
Robarts Research Institute
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5B7
Country
Canada
Facility Name
Centre Etudes Cliniques Ecogene-21
City
Chicoutimi
State/Province
Quebec
ZIP/Postal Code
G7H 7K9
Country
Canada
Facility Name
Clinique des maladies lipidiques de Quebec
City
Quebec
ZIP/Postal Code
G1V 4W2
Country
Canada
Facility Name
University Hospital Carl Gustav Carus
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
University Hospital of Leipzig
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
Amsterdam University Medical Center (Amsterdam UMC), Academic Medical Center (AMC)
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
Facility Name
Ziekenhuis Rijnstate
City
Arnhem
ZIP/Postal Code
6815 AD
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD Sharing Time Frame
When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
IPD Sharing Access Criteria
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD Sharing URL
https://vivli.org/

Learn more about this trial

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

We'll reach out to this number within 24 hrs